Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KITE-363 |
Synonyms | |
Therapy Description |
KITE-363 comprises autologous T-lymphocytes engineered to express chimeric antigen receptors (CARs) targeting CD19 and CD20 as well as the CD28 and 4-1BB costimulatory domains, which potentially results in killing of tumor cells expressing CD19 and/or CD20 (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS7579). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KITE-363 | KITE 363|KITE363 | CD19 Immune Cell Therapy 62 CD20 Immune Cell Therapy 11 | KITE-363 comprises autologous T-lymphocytes engineered to express chimeric antigen receptors (CARs) targeting CD19 and CD20 as well as the CD28 and 4-1BB costimulatory domains, which potentially results in killing of tumor cells expressing CD19 and/or CD20 (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS7579). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|